Celgene (CELG) Tops Q1 EPS by 4c; Raises Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Celgene Reports First Quarter 2017 Operating and Financial Results
April 27, 2017 7:27 AM EDT- Net Product Sales of $2.95B in Q1:17; Increased 18% Y/Y
- REVLIMID® Net Product Sales of $1.9B in Q1:17; Increased 20% Y/Y
- Raising 2017 EPS Guidance
- Positive phase II STEPSTONE data with ozanimod in Crohns disease; Phase III trial initiation planned by year-end
SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) reported net product sales of $2,950 million for the first quarter of 2017, an 18 percent increase from the same period in 2016. Net product sales... More
